HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry

Study Overview
=================
Brief Summary
-----------------
In this registry study the investigators will collect data about patients' disease, treatment, and response to treatment to include in both our local and national databases. These can then be used by investigators to answer questions about cytoreductive surgery/HIPEC such as how well-tolerated or effective it is in specific populations.

Detailed Description
-----------------
Patient Selection: The sole inclusion criteria for this study will be those consenting patients who are to undergo cytoreductive surgery followed by HIPEC. Data Collection and Use Plan: For those patients who provide informed consent, data listed below will be collected during and after treatment. This will be entered into the PI's local database for future use and, after being de-identified, will be shared with a national database (held by the American Society of Peritoneal Surface Malignancies) to bolster the amount available for researchers looking at efficacy and outcomes such as overall survival rates, progression-free survival, and tolerability in certain populations. Data Collected (as applicable): Age, primary tumor, dates of prior surgeries, prior chemotherapy with dates and whether it was neoadjuvant in nature, length of disease status, comorbidities, Peritoneal Surface Disease Severity Score, Peritoneal Cancer Index as determined prior to surgery, Peritoneal Cancer Index as determined during surgery, Completeness of Cytoreduction score, ascites present, blood products used, complications, length of stay in ICU and in hospital, where discharged, death within 30 days, readmission and reason, date of recurrence, treatment of recurrence, and time from procedure to death. For the HIPEC surgical procedure itself, data collected will be: date, duration, chemotherapeutic used and dose, duration of circulation, fluid temp, and flow rate.

Official Title
-----------------
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry

Conditions
-----------------
Peritoneal Neoplasms, Neoplasm Metastasis, Adenocarcinoma, Sarcoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible to undergo cytoreductive surgery followed by HIPEC performed by the PI at Edward Hospital Provides consent by signing informed consent form Exclusion Criteria: Not eligible for surgery or for potential cytoreductive surgery and/or HIPEC as determined by the PI Does not consent to participate
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival rate | Collect data from patients undergoing CRS/HIPEC which will be used to examine overall survival rates in specific patient populations. | From time of treatment until death, approximately 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival rate | Collect data from patients undergoing CRS/HIPEC which will be used to examine progression-free survival rates in specific patient populations | From time of treatment until time of disease progression, approximately 10 years | 
| Rates of complications | Collect data from patients to examine rates of complications in specific patient populations | During procedure until approximately 90 days post | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metastasis, Carcinomatosis, Carcinosis, Sarcomatosis, CRS, Cytoreductive surgery, HIPEC, Heated Intraperitoneal Chemotherapy, Intra-abdominal, Sugarbaker technique, Mitomycin C, Cisplatin, Doxorubicin, Oxaliplatin, Melphalan